COSCIENS BIOPHARMA INC (CSCIF) Financials

CSCIF

FY2025 annual

Revenue $7.5M -21.8% YoY

Net Income -$10.4M +32.3% YoY

Free Cash Flow -$9.2M +41.6% YoY

Operating Cash Flow -$8.5M +41.8% YoY

Market Cap $5.5M as of Sep 10, 2026

Price / Sales 0.7x on $7.5M revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.4x on $3.8M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 25, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Mar 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CSCIF SEC filings page.

COSCIENS BIOPHARMA INC (CSCIF) reported $7.5M in revenue for fiscal year 2025, down 21.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CSCIF FY2025 2026-09-05

Cash-consuming operations, not revenue growth, dominate: losses are shrinking equity while leverage becomes more material.

The FY2025 net loss of $10.4M exceeded operating cash outflow of $8.5M, so reported earnings include costs beyond the cash operating drain. That gap, alongside a free-cash-flow outflow of $9.2M, indicates cash is being consumed through both operations and reinvestment rather than solely through an accounting loss.

Revenue reached $14.6M in FY2022 while net margin was 23.7%, but that profit did not establish a stable earnings base. Net margin swung to -48.8% in FY2023. By FY2025, revenue was $7.5M and net margin was -138.1%, meaning losses remained larger than sales after the 2024 peak.

Equity fell from $13.2M in FY2024 to $3.8M in FY2025, so losses are eroding the balance-sheet cushion supporting operations. Debt-to-equity rose from 0.2x to 0.5x, making financing more consequential as equity shrank. The latest current ratio of 3.2x indicates short-term assets exceed current obligations, but does not offset the longer-term weakening visible in equity.

Financial Health Signals

Financial health score not available

COSCIENS BIOPHARMA INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/8

COSCIENS BIOPHARMA INC passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

COSCIENS BIOPHARMA INC reported a net loss of $10.4M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.8M

YoY-46.8%

QoQ+19.1%

COSCIENS BIOPHARMA INC generated $1.8M in revenue in Q4 2025. This represents a decrease of 46.8% from the same quarter a year earlier. Against the prior quarter it is up 19.1%.

Net Income

-$2.2M

YoY+67.6%

QoQ-20.0%

COSCIENS BIOPHARMA INC reported -$2.2M in net income in Q4 2025. This represents an increase of 67.6% from the same quarter a year earlier. Against the prior quarter it is down 20.0%.

EBITDA

Not reported for Q4 2025.

EPS (Diluted)

Not reported for Q4 2025.

Cash & Balance Sheet

Free Cash Flow

-$1.5M

YoY+54.2%

QoQ-122.9%

COSCIENS BIOPHARMA INC recorded an outflow of $1.5M in free cash flow in Q4 2025, representing a cash shortfall after capex. This represents an increase of 54.2% from the same quarter a year earlier. Against the prior quarter it is down 122.9%.

Cash & Debt

$7.3M

YoY-55.4%

QoQ-14.3%

5Y CAGR-21.3%

COSCIENS BIOPHARMA INC held $7.3M in cash against $1.9M in long-term debt as of Q4 2025.

Shares Outstanding

YoY+1.4%

QoQ0.0%

COSCIENS BIOPHARMA INC had 3M shares outstanding in Q4 2025. This represents an increase of 1.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

Return on Equity

-56.8%

YoY-5.7pp

QoQ-21.0pp

5Y change-46.9pp

COSCIENS BIOPHARMA INC's ROE was -56.8% in Q4 2025, measuring profit generated per dollar of shareholder equity. This is down 5.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 21.0 percentage points.

Gross Margin

Not reported for Q4 2025.

Operating Margin

Not reported for Q4 2025.

Net Margin

Not shown for Q4 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

Capital Expenditures

$46K

YoY-85.1%

QoQ+1050.0%

COSCIENS BIOPHARMA INC invested $46K in capex in Q4 2025, funding long-term assets and infrastructure. This represents a decrease of 85.1% from the same quarter a year earlier. Against the prior quarter it is up 1050.0%.

R&D Spending

Not reported for Q4 2025.

Share Buybacks

Not reported for Q4 2025.

CSCIF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CSCIF quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	$7.5M-21.8%	$9.6M+34.2%	$7.1M-51.0%	$14.6M+177.0%	$5.3M+44.0%	$3.7M+586.5%	$532K-98.0%	$26.9M+2812.4%	$923K+1.3%	$911K+67.2%	$545K
Interest Expense	$168K+30.2%	$129K-5.1%	$136K-4.9%	$143K+1942.9%	$7K-63.2%	$19K-71.2%	$66K-94.5%	$1.2M-57.2%	$2.8M-38.0%	$4.5M+129.4%	-$15.3M
Income Tax	$10K-88.1%	$84K+109.5%	-$885K-181.9%	$1.1M+1090.8%	-$109K-127.6%	$395K+310.1%	-$188K-103.4%	$5.5M+256.7%	-$3.5M	$0	$0
Net Income	-$10.4M+32.3%	-$15.3M-339.3%	-$3.5M-201.1%	$3.4M+141.2%	-$8.4M-63.5%	-$5.1M+15.3%	-$6.0M-244.3%	$4.2M+124.9%	-$16.8M+32.7%	-$25.0M+50.2%	-$50.1M
Diluted Shares (Avg)	3M+22.6%	3M+39.7%	2M-0.4%	2M	5M	41M+134.8%	17M+2.7%	17M+13.9%	15M+44.5%	10M	N/A

Metric	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q
Revenue	$1.8M-46.8%	$1.5M-20.7%	$2.7M+17.6%	$1.5M-27.1%	$3.3M+98.8%	$1.9M-4.1%	$2.3M+67.9%	$2.1M-3.3%
Interest Expense	$32K+45.5%	$43K+95.5%	$23K+4.5%	$70K+11.1%	$22K-83.9%	$22K-4.3%	$22K-8.3%	$63K+231.3%
Income Tax	N/A	N/A	$1K+100.2%	N/A	$1.1M	-$112K+47.2%	-$474K-101.7%	-$412K
Net Income	-$2.2M+67.6%	-$1.8M+68.4%	-$2.7M-89.9%	-$3.7M-160.9%	-$6.7M-379.8%	-$5.8M-641.6%	-$1.4M-65.3%	-$1.4M+67.1%
Diluted Shares (Avg)	N/A	3M+2.3%	3M+43.0%	3M+70.2%	N/A	3M+68.1%	2M+20.2%	2M+52.2%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).

CSCIF Balance Sheet

CSCIF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$21.4M-38.9%	$35.1M+47.7%	$23.7M-14.7%	$27.8M-65.2%	$80.1M+116.5%	$37.0M+85.2%	$20.0M-20.1%	$25.0M+12.7%	$22.2M-29.9%	$31.7M	N/A
Current Assets	$11.5M-52.0%	$24.0M+112.8%	$11.3M	N/A	$70.8M+156.5%	$27.6M+153.1%	$10.9M-32.9%	$16.3M+73.3%	$9.4M-58.8%	$22.7M	N/A
Cash & Equivalents	$7.3M-55.4%	$16.4M+145.5%	$6.7M-34.5%	$10.2M+65.5%	$6.2M-74.6%	$24.3M+209.7%	$7.8M-46.0%	$14.5M+86.5%	$7.8M-64.6%	$22.0M-46.9%	$41.5M
Inventory	$1.3M-51.4%	$2.7M-32.9%	$4.0M+1650.7%	$229K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.3M-46.5%	$2.4M+712.8%	$290K-60.4%	$732K-44.3%	$1.3M-21.8%	$1.7M+155.5%	$658K+123.8%	$294K+33.0%	$221K-39.5%	$365K	N/A
Goodwill	N/A	N/A	N/A	N/A	$8.1M-7.8%	$8.8M+9.5%	$8.1M-1.9%	$8.2M-4.7%	$8.6M+14.0%	$7.6M-3.6%	$7.8M
Total Liabilities	$17.6M-19.7%	$21.9M+708.5%	$2.7M-32.6%	$4.0M-85.2%	$27.1M+14.0%	$23.8M+6.0%	$22.4M-2.9%	$23.1M-7.5%	$25.0M-1.8%	$25.4M	N/A
Current Liabilities	$3.6M-50.0%	$7.2M+450.9%	$1.3M	N/A	$7.8M+63.8%	$4.7M-16.2%	$5.7M+1.1%	$5.6M-3.0%	$5.8M+37.2%	$4.2M	N/A
Non-Current Liabilities	$14.0M-4.8%	$14.7M+949.8%	$1.4M	N/A	$19.4M+1.6%	$19.1M+13.5%	$16.8M-4.1%	$17.5M-8.9%	$19.2M-9.6%	$21.2M	N/A
Long-Term Debt	$1.9M-5.1%	$2.0M+45.7%	$1.4M+2052.3%	$65K+109.7%	$31K-36.7%	$49K-80.8%	$255K	N/A	N/A	N/A	N/A
Total Equity	$3.8M-70.8%	$13.2M-37.4%	$21.0M-11.7%	$23.8M-55.0%	$53.0M+301.1%	$13.2M+636.4%	-$2.5M-229.2%	$1.9M+168.5%	-$2.8M-144.8%	$6.2M-71.3%	$21.6M
Retained Earnings	-$20.5M-69.3%	-$12.1M-378.0%	$4.4M+101.2%	-$352.1M-5.2%	-$334.6M-3.7%	-$322.7M-1.8%	-$316.9M-2.3%	-$309.8M+1.4%	-$314.2M-5.4%	-$298.1M	N/A

Metric	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q
Total Assets	$21.4M-38.9%	$23.9M-45.5%	$27.6M-44.9%	$31.1M-2.0%	$35.1M+47.7%	$43.8M+3.0%	$50.0M+7.7%	$31.8M-38.0%
Current Assets	$11.5M-52.0%	$13.8M-51.0%	$16.5M-50.3%	$20.4M-34.8%	$24.0M+112.8%	$28.2M-32.7%	$33.2M-27.6%	$31.2M-38.5%
Cash & Equivalents	$7.3M-55.4%	$8.5M-57.4%	$9.3M-66.4%	$13.8M+292.4%	$16.4M+145.5%	$20.0M+139.1%	$27.8M+225.7%	$3.5M-62.3%
Inventory	$1.3M-51.4%	$1.8M-46.8%	$1.8M-40.4%	$2.5M+3735.9%	$2.7M-32.9%	$3.3M	$3.1M	$64K
Accounts Receivable	$1.3M-46.5%	$1.6M-15.2%	$2.8M+124.8%	$1.9M+878.4%	$2.4M+712.8%	$1.9M+246.5%	$1.2M+569.2%	$190K-65.9%
Total Liabilities	$17.6M-19.7%	$18.8M-20.9%	$20.5M-14.1%	$21.0M+11.6%	$21.9M+708.5%	$23.8M+46.6%	$23.8M+36.9%	$18.8M-6.2%
Current Liabilities	$3.6M-50.0%	$4.0M-51.2%	$5.5M-44.1%	$7.1M+34.4%	$7.2M+450.9%	$8.2M+93.2%	$9.9M+142.8%	$5.3M-18.4%
Non-Current Liabilities	$14.0M-4.8%	$14.8M-5.1%	$14.9M+7.2%	$13.9M+2.7%	$14.7M+949.8%	$15.6M+30.1%	$13.9M+4.4%	$13.6M-0.5%
Long-Term Debt	$1.9M-5.1%	$2.0M+61.8%	$2.0M+60.1%	$2.0M+2366.3%	$2.0M+45.7%	$1.2M+1630.0%	$1.3M+1405.9%	$80K+5.3%
Total Equity	$3.8M-70.8%	$5.1M-74.6%	$7.1M-72.9%	$10.1M-47.1%	$13.2M-37.4%	$20.0M-9.3%	$26.2M+12.2%	$19.2M-38.5%
Retained Earnings	-$20.5M-69.3%	-$19.0M-269.3%	-$17.2M-1223.7%	-$14.7M+96.1%	-$12.1M-378.0%	-$5.2M+98.6%	$1.5M+100.4%	-$375.3M-5.3%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.

CSCIF Cash Flow Statement

CSCIF quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$8.5M+41.8%	-$14.6M-464.2%	-$2.6M-149.4%	$5.2M+160.9%	-$8.6M-107.8%	-$4.1M+61.5%	-$10.7M-257.1%	$6.8M+129.8%	-$22.9M+21.0%	-$29.0M+14.3%	-$33.8M
Depreciation & Amortization	$1.2M-26.1%	$1.6M+11.4%	$1.4M-1.7%	$1.5M+912.4%	$145K-37.5%	$232K-26.3%	$315K+443.1%	$58K-38.3%	$94K-66.4%	$280K-17.9%	$341K
Capital Expenditures	$706K-39.2%	$1.2M+60.8%	$722K+137.5%	$304K+913.3%	$30K	N/A	N/A	$9K+125.0%	$4K-93.9%	$66K+153.8%	$26K
Free Cash Flow	-$9.2M+41.6%	-$15.7M-376.1%	-$3.3M-167.1%	$4.9M+157.2%	-$8.6M	N/A	N/A	$6.8M+129.7%	-$22.9M+21.2%	-$29.1M+14.2%	-$33.9M
Investing Cash Flow	-$458K-101.8%	$25.1M+3536.0%	-$730K-140.1%	-$304K+53.8%	-$658K-1275.0%	$56K+12.0%	$50K+242.9%	-$35K-111.4%	$307K+197.8%	-$314K-134.4%	$913K
Financing Cash Flow	-$407K+30.8%	-$588K-64.7%	-$357K-33.7%	-$267K-100.5%	$51.0M+149.4%	$20.5M+425.8%	$3.9M	$0-100.0%	$8.0M-19.1%	$9.9M-75.7%	$40.8M

Metric	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q
Operating Cash Flow	-$1.5M+51.0%	-$676K+91.3%	-$4.4M-220.2%	-$1.9M+21.0%	-$3.0M-176.4%	-$7.8M-5502.1%	-$1.4M-70.8%	-$2.4M+41.4%
Depreciation & Amortization	$289K-26.3%	$287K-40.1%	$287K-23.9%	$325K-9.5%	$392K+9.2%	$479K+32.0%	$377K+4.1%	$359K+797.5%
Capital Expenditures	$46K-85.1%	-$4K-96.9%	$49K-68.8%	$615K+9.0%	$309K-47.4%	$131K+162.0%	$157K+190.7%	$564K+28100.0%
Free Cash Flow	-$1.5M+54.2%	-$680K+91.4%	-$4.5M-190.8%	-$2.5M+15.3%	-$3.3M-97.8%	-$7.9M-8514.9%	-$1.5M-78.3%	-$2.9M+27.5%
Investing Cash Flow	$201K+163.6%	$4K-95.2%	-$48K-100.2%	-$615K-9.0%	-$316K+46.9%	$83K+266.0%	$25.9M+48025.9%	-$564K-28100.0%
Financing Cash Flow	-$15K+92.6%	-$85K+54.8%	-$107K+15.1%	-$200K-112.8%	-$202K-22.4%	-$188K-218.6%	-$126K-80.0%	-$94K-147.4%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

CSCIF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CSCIF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Net Margin	-138.1%	-159.7%	-48.8%-72.5pp	23.7%	-159.1%	-140.1%	-1135.7%	15.6%	-1819.7%	-2739.7%	-9200.5%
Return on Equity	-269.6%-153.3pp	-116.3%-99.8pp	-16.6%-31.0pp	14.5%+30.3pp	-15.8%+22.9pp	-38.7%	N/A	219.6%	N/A	-401.8%-169.8pp	-232.0%
Return on Assets	-48.3%-4.7pp	-43.6%-29.0pp	-14.7%-27.1pp	12.4%+22.8pp	-10.4%+3.4pp	-13.8%+16.4pp	-30.2%-47.0pp	16.7%+92.4pp	-75.7%+3.2pp	-78.8%	N/A
Current Ratio	3.18-0.1x	3.32-5.3x	8.59	N/A	9.12+3.3x	5.82+3.9x	1.93-1.0x	2.90+1.3x	1.63-3.8x	5.41	N/A
Debt-to-Equity	0.50+0.3x	0.15+0.1x	0.07+0.1x	0.000.0x	0.000.0x	0.00	N/A	12.12	N/A	4.10	N/A
Asset Turnover	0.35+0.1x	0.270.0x	0.30-0.2x	0.52+0.5x	0.070.0x	0.10+0.1x	0.03-1.0x	1.07+1.0x	0.040.0x	0.03	N/A
FCF Margin	-122.4%	-164.1%	-46.3%-80.1pp	33.8%	-163.7%	N/A	N/A	25.4%	-2482.9%	-3191.7%	-6214.7%

Metric	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q
Net Margin	-123.6%	-122.7%	-98.3%-37.4pp	-243.7%	-202.6%	-307.6%	-60.9%+0.9pp	-68.1%
Return on Equity	-56.8%-5.7pp	-35.8%-7.1pp	-38.1%-32.6pp	-36.0%-28.7pp	-51.1%-62.6pp	-28.7%-25.2pp	-5.4%-1.7pp	-7.3%+6.3pp
Return on Assets	-10.2%+9.0pp	-7.6%+5.5pp	-9.8%-7.0pp	-11.7%-7.3pp	-19.2%-29.3pp	-13.2%-11.3pp	-2.8%-1.0pp	-4.4%+3.9pp
Current Ratio	3.18-0.1x	3.470.0x	2.98-0.4x	2.88-3.1x	3.32-5.3x	3.46-6.5x	3.35-7.9x	5.94-1.9x
Debt-to-Equity	0.50+0.3x	0.39+0.3x	0.29+0.2x	0.19+0.2x	0.15+0.1x	0.06+0.1x	0.050.0x	0.000.0x
Asset Turnover	0.080.0x	0.060.0x	0.10+0.1x	0.050.0x	0.090.0x	0.040.0x	0.050.0x	0.060.0x
FCF Margin	-85.8%+13.7pp	-45.9%	-163.5%	-166.3%	-99.6%	-422.8%	-66.1%-3.9pp	-143.1%

Not reported in any period shown, so not listed: Gross Margin, Operating Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.

Where COSCIENS BIOPHARMA INC Ranks

Frequently Asked Questions

What is COSCIENS BIOPHARMA INC's annual revenue?

COSCIENS BIOPHARMA INC (CSCIF) reported $7.5M in total revenue for fiscal year 2025. This represents a -21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is COSCIENS BIOPHARMA INC's revenue growing?

COSCIENS BIOPHARMA INC (CSCIF) revenue declined by 21.8% year-over-year, from $9.6M to $7.5M in fiscal year 2025.

Is COSCIENS BIOPHARMA INC profitable?

No, COSCIENS BIOPHARMA INC (CSCIF) reported a net income of -$10.4M in fiscal year 2025.

How much debt does COSCIENS BIOPHARMA INC have?

As of fiscal year 2025, COSCIENS BIOPHARMA INC (CSCIF) had $7.3M in cash and equivalents against $1.9M in long-term debt.

What is COSCIENS BIOPHARMA INC's return on equity (ROE)?

COSCIENS BIOPHARMA INC (CSCIF) has a return on equity of -269.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is COSCIENS BIOPHARMA INC's free cash flow?

COSCIENS BIOPHARMA INC (CSCIF) recorded an outflow of $9.2M in free cash flow during fiscal year 2025. This represents a 41.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is COSCIENS BIOPHARMA INC's operating cash flow?

COSCIENS BIOPHARMA INC (CSCIF) recorded an outflow of $8.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are COSCIENS BIOPHARMA INC's total assets?

COSCIENS BIOPHARMA INC (CSCIF) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are COSCIENS BIOPHARMA INC's capital expenditures?

COSCIENS BIOPHARMA INC (CSCIF) invested $706K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does COSCIENS BIOPHARMA INC have outstanding?

COSCIENS BIOPHARMA INC (CSCIF) had 3M shares outstanding as of fiscal year 2025.

What is COSCIENS BIOPHARMA INC's current ratio?

COSCIENS BIOPHARMA INC (CSCIF) had a current ratio of 3.18 as of fiscal year 2025, which is generally considered healthy.

What is COSCIENS BIOPHARMA INC's debt-to-equity ratio?

COSCIENS BIOPHARMA INC (CSCIF) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is COSCIENS BIOPHARMA INC's return on assets (ROA)?

COSCIENS BIOPHARMA INC (CSCIF) had a return on assets of -48.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is COSCIENS BIOPHARMA INC's P/E ratio?

COSCIENS BIOPHARMA INC (CSCIF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $5.5M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is COSCIENS BIOPHARMA INC's price-to-sales ratio?

COSCIENS BIOPHARMA INC (CSCIF) trades at 0.7x sales, its market capitalization divided by revenue of $7.5M revenue, FY2025. The market capitalization is $5.5M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is COSCIENS BIOPHARMA INC's Piotroski F-Score?

COSCIENS BIOPHARMA INC (CSCIF) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are COSCIENS BIOPHARMA INC's earnings high quality?

COSCIENS BIOPHARMA INC (CSCIF) reported a net loss of $10.4M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.